Daratumumab in rituximab‐refractory autoimmune haemolytic anaemia

Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus

(2020) Lennard Ostendorf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis

(2019) Franziska Scheibe et al.   JOURNAL OF NEUROLOGY

Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting

(2019) Ulrich Jäger et al.   BLOOD REVIEWS

Targeting B Cells and Plasma Cells in Autoimmune Diseases

(2018) Katharina Hofmann et al.   Frontiers in Immunology

Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation

(2018) Claudia I. Chapuy et al.   NEW ENGLAND JOURNAL OF MEDICINE

The diagnosis and management of primary autoimmune haemolytic anaemia

(2016) Quentin A. Hill et al.   BRITISH JOURNAL OF HAEMATOLOGY

A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins

(2016) A.S. Rosenberg et al.   CLINICAL IMMUNOLOGY

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases

(2009) M. Michel et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD